A Randomized,Subject And Investigator Blind, Sponsor Open Placebo Controlled, Parallel Phase 1b Study To Examine The Safety, Pharmacokinetics, And Pharmacodynamic Effects Of Pf‑06412562 On Cognitive And Reward/Motivation Domains In Healthy Male Volunteers Selected By Cognitive Phenotype
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs PF 6412562 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 27 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016.
- 27 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2016.